Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 118 Matches

Quinine

Model Files Publication

Brand Name(s) include: Qualaquin

Disease: Malaria

Drug Class: Antimalarials

Date Updated: 2021

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Minimal PBPK (Method 1)
Route of Elimination	CYP3A4 (fm = 0.50); renal clearance (fe = 0.1)
Perpetrator DDI	CYP2D6 Inhibitor
Validation	Three clinical studies describing Quinine PK were identified for model verification. Three clinical DDI studies where quinine was the victim of CYP-mediated DDIs were used to verify the PBPK model. All studies were well recovered with simulated Cmax and AUC GMRs within 1.5-fold of the observed
Limitations	The Simcyp quinine PBPK model was able to recover interactions CYP3A inducers and inhibitors with reasonable accuracy. Verification needed for perpetrator DDI assessment as literature data is unavailable at this time.
Updates in V19	Updated in vitrodata fup: 0.199 -> 0.37 Caco-2 A -> B Permeability: 70 x 10-6 cm/s -> 39 x 10-6 cm/s Propranolol reference Permeability: 101 x 10-6 cm/s -> 45 x 10-6 cm/s Minimal PBPK with Vss predicted through Method 1 Updated retrograde clearance

Search Score: 1

Rilpivirine

Model Files Publication

Brand Name: Edurant, Rekambys

Disease: HIV

Drug Class: non-nucleoside reverse transcriptase inhibitor

Version: 21

Date Updated: March 2024

The model at-a-glance

Absorption Model	First order
Volume of Distribution Details	Full PBPK (Method 3)
Route of Elimination	CYP3A4 = 63.2%; Additional HLM = 36.8%
Perpetrator DDI	CYP3A4 Inhibition CYP3A4 Induction
Validation	The refined model was able to recover clinically observed concentration-time profiles of rilpivirine following single and multiple dosing. Seven clinical DDI studies where rilpivirine was administered with either efavirenz, ketoconazole, rifampin, or rifabutin were used to verify the PBPK model of rilpivirine as a victim. In comparison of predicted vs. observed AUC, 85.7% of the studies were within 1.5-fold. Three clinical DDI studies where rilpivirine was administered with either sildenafil, ethinylestradiol, or midazolam were used to verify the PBPK model of rilpivirine as a perpetrator. In comparison of predicted vs. observed AUC, 100% of the studies were within 1.25-fold.
Limitations	The net in vivo effect of rilpivirine as either an inhibitor or an inducer of CYP3A appears to be negligible based on the available DDI studies

Search Score: 1

ItraconazoleAndTwoMetabolites_V17R1_AstraZeneca_20191113

Model Files Publication

Capsule and solution formulation of itraconazole in different compound files. 2 Metabolites: OH-itraconazole and KETO-itraconazole. Note: If you wish to add both itraconazole metabolites then itraconazole has to be placed as substrate. https://doi.org/10.1124/dmd.118.081364

Search Score: 1

Eltrombopag_RES_V21R1_Simcyp_20230615

Model Files Publication

Prepared: June 2023 The RES-Eltrombopag_V21 model has been developed primarily as an inhibitor of hepatic OATP1B1 and OATP1B3, and intestinal BCRP using the New GI physiology in Simcyp V21 with altered GI tract population inputs that became default in V22. The file is verified as tablet in the fasted state as that formulation was used in the Rosuvastatin DDI (Allred et al., 2011). The PK for Eltrombopag was evaluated at 25mg, 50mg and 75mg SD; 50mg QD, 100mg QD, 150mg QD, and 200mg QD. Note, the Rosuvastatin DDI with 75mg QD was used to fit the BCRP component in Rosuvastatin V21 file using the New GI physiology. The BCRP component of Rosuvastatin was then verified with other BCRP-Inhibitors available on the members area (as specified in the attached document) or within the Simcyp Simulator. Allred, A. J., C. J. Bowen, J. W. Park, B. Peng, D. D. Williams, M. B. Wire, and E. Lee. 2011. “Eltrombopag Increases Plasma Rosuvastatin Exposure in Healthy Volunteers.” Journal Article. Br J Clin Pharmacol 72 (2): 321–29.

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Quinine

The model at-a-glance

Rilpivirine

The model at-a-glance

ItraconazoleAndTwoMetabolites_V17R1_AstraZeneca_20191113

Eltrombopag_RES_V21R1_Simcyp_20230615

Your Privacy